Reversal of in vivo drug resistance by the transforming growth factor-β inhibitor decorin

International Journal of Cancer

Volumn 71, Issue 1, 1997, Pages 49-58

  Teicher, Beverly A ^a   Maehara, Yoshihiko ^a   Kakeji, Yoshihiro ^a   Ara, Gulshan ^a   Keyes, Susan R ^a   Wong, Julia ^a   Herbst, Roy ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DECORIN; MESSENGER RNA; RECOMBINANT DECORIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DRUG SENSITIVITY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VIVO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL SURVIVAL; CISPLATIN; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX PROTEINS; FEMALE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; PROTEOGLYCANS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0030993935     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970328)71:1<49::AID-IJC10>3.0.CO;2-4     Document Type: Article

References (29)

1. ANSCHER, M.S. and JIRTLE, R.L., Role of transforming growth factor-β and hepatocyte growth factor in late normal tissue effects of radiation. Radiat. Oncol. Invest., 1, 305-313 (1994).
2. ANSCHER, M.S., MURASE, T., PRESCOTT, D.M., MARKS, L.B., REISENBICHLER, H., BENTEL, G.C., SPENCER, D., SHEROUSE, G. and JIRTLE, R.L., Changes in plasma TGFβ levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis. Int. J. Radiat. Oncol. Biol. Phys., 30, 671-676 (1994).
3. ANSCHER, M.S., PETERS, W.P. REISENBICHLER, H., PETROS, W.P. and JIRTLE, R.L., Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N. Engl. J. Med., 328, 1592-1598 (1993).
4. BECK, L.S., DEGUZMAN, L., LEE, W.P., Xu, Y., SIEGEL, M.W. and AMENTO, E.P., One systemic administration of transforming growth factor-β I reverses age- or glucocorticoid-impaired wound healins. J. clin. Invest., 92, 2841-2849 (1993).
5. BITTNER, K., LISZIO, C., BLUMBERG, P., SCHÖNHERR, E. and KRESSE, H., Modulation of collagen sel contraction by decorin. Biochem. J., 314, 159-166 (1996).
6. BORDER, W.A. and NOBLE, N.A., Transforming growth factor β in tissue fibrosis. N. Engl. J. Med., 331, 1286-1292 (1994).
7. BORDER, W.A., NOBLE. N.A., YAMAMOTO, K., HARPER, J.R., YAMAGUCHI. Y., PIERSCHBACHER, M.D. and RUOSLAHTI, E., Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature (Lond.), 360, 361-364 (1992).
8. CHATTERJEE, D., Liu, J.T., NORTHEY, D. and TEICHER, B.A., Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors. Cancer Chemother. Pharmacol., 35, 423-431 (1995).
9. FREGENE, T.A., KHANUJA, P.S., GIMOTTY, P.A., KELLOGG, C., GEORGE, J. and PIENTA, K.J., The relationship of microvessel counts to tumor size, estrogen receptor status, lumph node metastasis, and disease-free survival in patients with stage I and II breast cancer. Int. J. Oncol., 5, 1437-1445 (1994).
10. HERMAN, M.E. and KATZENELLENBOGEN, B.S., Alterations in transforming growth factor-ex and -β production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res., 54, 5867-5874 (1994).
11. IOZZO, R. and COHEN, I., Altered proteogiycan gene expression and the tumor stroma. Experientia, 49, 447-455 (1993).
12. ISAKA, Y., BREES, D., IKEGAYA, K., KANEDA, Y., IMAI, E., NOBLE, N. and BORDER, W., Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature (Lond.), 2, 418-423 (1996).
13. MCBRIDE, W.H., Cytokine cascades in late normal tissue radiation responses, Int J. Radiat. Oncol. Biol. Phys., 33, 233-234 (1995).
14. MERZAK, A., MCCREA, S., KOOCHECKPOUR, S. and PILKINGTON, G.J., Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor β1. Brit. J. Cancer, 70, 199-203 (1994).
15. MIETTINEN, M., LINDENMAYER, A.E. and CHAUBAL, A., Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens: evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod. Pathol., 7, 82-90 (1994).
16. MUIR, G.H., BUTTA, A., SHEARER, R.J., FISHER, C., DEARNALEY, D.P., FLANDERS, K.C., SPORN, M.B. and COLLETTA, A.A., Induction of transforming growth factor beta in hormonally treated human prostate cancer. Brit. J. Cancer, 69, 130-134 (1994).
17. RANDALL, K. and COGGLE, J.E., Expression of transforming growth factor-β1 in mouse skin during the acute phase of radiation damage. Int. J. Radiat. Biol., 68, 301-309 (1995).
18. RODEMANN, H.P. and BAMBERG, M., Cellular basis of radiation-induced fibrosis. Radiother. Oncol 35, 83-90 (1995).
19. RUBIN, P., JOHNSTON, C.J., WILLIAMS, J.P., MCDONALD, S. and FINKELSTEIN, J.N., A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int. J. Radiat. Oncol. Biol. Phys., 33, 99-109 (1995).
20. SANTRA, M., SKORSKI, T., CALABRETTA, B., LATTIME, E. and Iozzo, R., De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc. nat. Acad. Sci. (Wash.), 92, 7016-7020 (1995).
21. SCHÖNHERR, E., HAUSSER, H., BEAVAN, L. and KRESSE, H., Decorin type I collagen interaction. J. biol. Chem., 270, 8877-8883 (1995).
22. SPORN, M.B. and ROBERTS, A.B., A major advance in the use of growth factors to enhance wound healing. J. clin. Invest., 92, 2565-2566 (1993).
23. TAKEUCHI, Y., KODAMA, Y. and MATSUMOTO, T., Bone matrix decorin binds TGF-β and enhances its bioactivity. J. biol. Chem., 269, 32634-32638 (1994).
24. TEICHER, B.A., In vivo resistance to antitumor alkylatins agents. In: B.A. Teicher (eds.). Drug resistance in oncology, pp. 263-290, M. Dekker, New York (1993).
25. TEICHER, B.A., CHATTERJEE, D., LIU, J.-T., HOLDEN, S.A. and ARA, G., Protection of bone-marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-aaent-resistant EMT-6 tumors. Cancer Chemother. Pharmacol., 32, 315-319 (1993).
26. TEICHER, B.A., HERMAN, T.S., HOLDEN, S.A., WANG, Y., PFEFFER, M.R., CRAWFORD, J.M. and FREI III, E., Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science, 247, 1457-1461 (1990).
27. TEICHER, B.A., HOLDEN, S.A., ARA, G. and CHEN, G., Transforming growth factor-β in in vivo resistance. Cancer Chemother. Pharmacol., 37, 601-609 (1996).
28. WELCH, D.R., FABRA, A. and MOTOWO, N., Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc. nat. Acad. Sci. (Wash.), 87, 7678-7682 (1990).
29. YAMAGUCHI, Y. MANN, D.M. and RUOSLAHTI, E., Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature (Lond.), 346, 281-284 (1990).